摘要
目的评价1个新的卵巢恶性肿瘤抗原——乳腺癌易感基因1（BRCA1）相关的具有环状结构域的蛋白（BARD1）剪切变异体（OV-142）的自身抗体在卵巢恶性肿瘤诊断中的价值。方法RT-PCR技术克隆OV-142基因的开放阅读框，构建OV．142的原核表达质粒，表达、纯化OV-142重组融合蛋白；用间接酶联免疫吸附试验检测126例卵巢恶性肿瘤患者、15例卵巢交界性肿瘤患者、42例卵巢良性肿瘤患者血清中OV-142的IgG、IgM型自身抗体的相对含量，并分析自身抗体在卵巢恶性肿瘤诊断中的临床价值。结果成功构建了OV-142的原核表达质粒，并获得了OV-142重组融合蛋白。当联合分析OV．142IgC型自身抗体与CA125时，在卵巢恶性肿瘤诊断中的敏感性为71．4％，高于单独分析Igo（41．3％）或CA。25（61．1％）；特异性为89．1％，高于单独分析IgG（84．2％）或CA。（88．0％）；准确性为81．9％，高于单独分析IgG（66．8％）或CA，25（77．1％）。结论OV-142是BARD1的1个剪切变异体，其有可能成为卵巢恶性肿瘤免疫治疗的新靶点。OV．142抗原的IgG型自身抗体在卵巢恶性肿瘤诊断中有可能成为CA125的1个重要的补充血清学标志物。
Objective To investigate the value of autoantibody of breast cancer susceptibility 1- associated RING domain （BARD1） splice variant （OV-142） in detection of ovarian cancer. Methods We cloned OV-142 gene into plasmid pET-30b（ ＋ ）. The recombinant protein of OV-142 was expressed in pET- 30b（ ＋ ） system and purified. The autoantibody of OV-142 was detected by indirect enzyme-linked immunosorbent assay （ELISA）. Results We successfully constructed the recombinant plasmid of OV-142. The recombinant protein was expressed in pET-30b （ ＋ ） system and purified. The purification rate of the recombinant protein was up to 90%. The relative amount of autoantibody of OV-142 detected by indirect ELISA was analyzed by receiver operating characteristic curve （ROC） and the cutoff value was determined. Combination of the autoantibody IgG of OV-142 and CA125 was analyzed by logistic regressian. The sensitivity, specificity and accuracy was 71.4%, 89. 1%, and 81.9%, respectively, which were higher than IgG （41.3%, 84. 2%, 66. 8% ） and CA125 （61.1%, 88.0%, 77.1% ） when used alone each. Conclusions OV-142 is a splice variant of BARD1. It may be a potential immunotherapy target of ovarian cancer. Detection of autoantibody of OV-142 is a potent complementary tool of CA125 in ovarian cancer diagnosis.
出处
《中华妇产科杂志》
CAS
CSCD
北大核心
2008年第9期680-684,共5页
Chinese Journal of Obstetrics and Gynecology
基金
广西科学研究与技术开发计划（桂科基0639043）
关键词
卵巢肿瘤
肿瘤抑制蛋白质类
抗原
肿瘤
自身抗体
Ovarian neoplasms
Tumor suppressor proteins
Antigens, neoplasm
Autoantibodies
